KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Profit After Tax: 2019-2024

Historic Profit After Tax for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to -$463.7 million.

  • Recursion Pharmaceuticals' Profit After Tax fell 69.29% to -$162.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.5 million, marking a year-over-year decrease of 89.42%. This contributed to the annual value of -$463.7 million for FY2024, which is 41.33% down from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Profit After Tax stood at -$463.7 million for FY2024, which was down 41.33% from -$328.1 million recorded in FY2023.
  • Recursion Pharmaceuticals' Profit After Tax's 5-year high stood at -$87.0 million during FY2020, with a 5-year trough of -$463.7 million in FY2024.
  • Its 3-year average for Profit After Tax is -$343.7 million, with a median of -$328.1 million in 2023.
  • Data for Recursion Pharmaceuticals' Profit After Tax shows a maximum YoY tumbled of 114.33% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Recursion Pharmaceuticals' Profit After Tax stood at -$87.0 million in 2020, then plummeted by 114.33% to -$186.5 million in 2021, then decreased by 28.42% to -$239.5 million in 2022, then tumbled by 36.99% to -$328.1 million in 2023, then slumped by 41.33% to -$463.7 million in 2024.